Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Esophageal Squamous Cell Carcinoma · Unresectable Locally Advanced Esophageal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanghai Chest Hospital, Shanghai, China
Contact: Study coordinator (Wen Yu, M.D) · yuzhiwen0827@163.com · 021-22200000-3203

Study leads

Wen Yu, M.D
Principal Investigator
Shanghai Chest Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Renal Cell Carcinoma · Non Small Cell Lung Cancer · Melanoma

Abroad (travel likely)RecruitingPHASE2

Pittsburgh, United States

DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

Esophageal Cancer

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Nanjing, China